奥泰生物：拟1-2亿元回购股份用于减少注册资本

Group 1 - The company announced that its controlling shareholder, actual controller, and chairman Gao Fei proposed a share buyback through centralized bidding, which has been approved by the shareholders' meeting [1] - The buyback amount will not be less than 100 million yuan and not exceed 200 million yuan, with a price not exceeding 85 yuan per share, expecting to repurchase between 1.1765 million and 2.3529 million shares, accounting for 1.48%-2.97% of the total share capital [1] - The funds for the buyback will come from the excess funds raised from the initial public offering, aimed at reducing registered capital [1] Group 2 - The buyback period will last for 12 months from the date of approval by the shareholders' meeting, and relevant personnel have no plans to reduce their holdings in the next 3 to 6 months [1] - There are risks associated with price changes and plan modifications regarding the buyback [1]